Skip to main content

Table 1 Demographics characteristics by clinical diagnosis

From: PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

 

HC

PD

AD

DLB

P-value

Pair-wise comparison*

 

(N = 5)

(N = 5)

(n = 10)

(n = 11)

  

Age

66.40 (11.67)

68.20 (7.76)

75.70 (9.46)

70.18 (9.02)

0.2333

 

% female

100

20

50

36.36

0.0558

a,c

Education (number of years. high school = 12, college = 16)

16.40 (0.89)

17.20 (1.10)

15.40 (2.50)

15.09 (3.15)

0.4252

 

Disease duration** mean (range)

NA

1.94 (0.93-2.75)

2.08 (0.35-4.47)

1.98 (0.74-3.65)

0.9944

 

MMSE; mean (SD)

29.60 (0.55)

29.80 (0.45)

20.10 (3.57)

18.36 (8.94)

0.0002

b,c,d,e

UPDRS; mean (SD)

1.40 (2.61)

30.60 (9.74)

18.90 (20.72)

61.46 (20.54)

<0.0001

a,b,c,d,e,f

  1. MMSE = mini-mental status examination; UPDRS = Unified Parkinson Disease Rating Scalep-value from Kruskal-Wallis test and Fisher exact test.
  2. *Letters indicate pairwise comparisons significant at p < 0.05; a = HC vs. PD; b = HC vs. AD; c = HC vs. DLB; d = PD vs. AD; e = PD vs. DLB; f = AD vs. DLB.
  3. **Years since diagnosis.